局部晚期宫颈癌治疗前血液学参数对确定性化疗反应的预测价值：前瞻性研究

IF 0.4 Q4 ONCOLOGY

International Journal of Cancer Management Pub Date : 2024-05-20 DOI:10.5812/ijcm-143466

K. Novin, Pedram Fadavi, Nafiseh Mortazavi, A. Arefpour, Hamidreza Dehghan, Mohadeseh Shahin, Somayeh Mohammad Taheri

{"title":"局部晚期宫颈癌治疗前血液学参数对确定性化疗反应的预测价值：前瞻性研究","authors":"K. Novin, Pedram Fadavi, Nafiseh Mortazavi, A. Arefpour, Hamidreza Dehghan, Mohadeseh Shahin, Somayeh Mohammad Taheri","doi":"10.5812/ijcm-143466","DOIUrl":null,"url":null,"abstract":"Background: More than 90% of cervical cancers are related to chronic inflammation caused by HPV. Several studies have shown that laboratory hematological parameters can detect the severity of systemic inflammation. Objectives: Our current cohort study investigated the predictive role of pretreatment hematological parameters for response to definitive chemoradiotherapy in patients with locally advanced cervical cancer (LACC). Methods: Prospectively, patients with LACC who candidates for definitive chemoradiation at Shohadaye Haftom-e-Tir are and Firozgar Hospitals (Tehran, Iran) were included in our study between April 2021 and December 2022. Hematological parameters were obtained from the blood sample test and peripheral blood smear before treatment. All patients diagnosed in stage IB to IVA received a similar treatment protocol and follow-up. Patients were divided into complete clinical (CR) and non-complete clinical responses (Non-CR). Leukocyte, Lymphocyte, neutrophil, platelet, hemoglobin (Hb), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR), were documented and then compared between two groups of responders. We used receiver operating characteristic (ROC) analysis to investigate the predictive value of these hematological parameters. Results: Out of 34 patients who met the inclusion criteria, 25 (73/5%) patients were complete responders and 9 (26.5%) were non-complete responders. The average number of neutrophils, leukocytes, and NLR was significantly higher among Non-complete responders. Hemoglobin in patients with non-complete responses was significantly lower than that of the other group of responders. Receiver operating characteristic curve analysis showed that the optimized cut-off values for pretreatment Hb and NLR were 11 and 2.1, respectively. Neutrophil-to-lymphocyte ratio cut-off point > 2.1 is significantly associated with larger tumor size, low Hb, high platelet, and high leukocyte. Conclusions: hematological markers such as NLR can be a simple and inexpensive predictive factor to evaluate therapeutic response to chemoradiation in LACC patients.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictive Value of Pre-treatment Hematological Parameters for Response to Definitive Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Study\",\"authors\":\"K. Novin, Pedram Fadavi, Nafiseh Mortazavi, A. Arefpour, Hamidreza Dehghan, Mohadeseh Shahin, Somayeh Mohammad Taheri\",\"doi\":\"10.5812/ijcm-143466\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: More than 90% of cervical cancers are related to chronic inflammation caused by HPV. Several studies have shown that laboratory hematological parameters can detect the severity of systemic inflammation. Objectives: Our current cohort study investigated the predictive role of pretreatment hematological parameters for response to definitive chemoradiotherapy in patients with locally advanced cervical cancer (LACC). Methods: Prospectively, patients with LACC who candidates for definitive chemoradiation at Shohadaye Haftom-e-Tir are and Firozgar Hospitals (Tehran, Iran) were included in our study between April 2021 and December 2022. Hematological parameters were obtained from the blood sample test and peripheral blood smear before treatment. All patients diagnosed in stage IB to IVA received a similar treatment protocol and follow-up. Patients were divided into complete clinical (CR) and non-complete clinical responses (Non-CR). Leukocyte, Lymphocyte, neutrophil, platelet, hemoglobin (Hb), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR), were documented and then compared between two groups of responders. We used receiver operating characteristic (ROC) analysis to investigate the predictive value of these hematological parameters. Results: Out of 34 patients who met the inclusion criteria, 25 (73/5%) patients were complete responders and 9 (26.5%) were non-complete responders. The average number of neutrophils, leukocytes, and NLR was significantly higher among Non-complete responders. Hemoglobin in patients with non-complete responses was significantly lower than that of the other group of responders. Receiver operating characteristic curve analysis showed that the optimized cut-off values for pretreatment Hb and NLR were 11 and 2.1, respectively. Neutrophil-to-lymphocyte ratio cut-off point > 2.1 is significantly associated with larger tumor size, low Hb, high platelet, and high leukocyte. Conclusions: hematological markers such as NLR can be a simple and inexpensive predictive factor to evaluate therapeutic response to chemoradiation in LACC patients.\",\"PeriodicalId\":44764,\"journal\":{\"name\":\"International Journal of Cancer Management\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2024-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5812/ijcm-143466\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-143466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：90% 以上的宫颈癌与人乳头瘤病毒引起的慢性炎症有关。多项研究表明，实验室血液学参数可检测全身炎症的严重程度。我们的目标是我们目前的队列研究调查了局部晚期宫颈癌（LACC）患者治疗前血液学参数对明确化放疗反应的预测作用。研究方法前瞻性地将 2021 年 4 月至 2022 年 12 月期间在 Shohadaye Haftom-e-Tir are 和 Firozgar 医院（伊朗德黑兰）接受明确化疗的局部晚期宫颈癌患者纳入研究。血液学参数来自治疗前的血样检测和外周血涂片。所有确诊为 IB 期至 IVA 期的患者都接受了类似的治疗方案和随访。患者被分为完全临床反应（CR）和非完全临床反应（Non-CR）。记录白细胞、淋巴细胞、中性粒细胞、血小板、血红蛋白（Hb）、血小板与淋巴细胞比值（PLR）和中性粒细胞与淋巴细胞比值（NLR），然后比较两组应答者。我们使用接收器操作特征（ROC）分析来研究这些血液学参数的预测价值。结果在符合纳入标准的 34 例患者中，25 例（73/5%）为完全应答者，9 例（26.5%）为非完全应答者。非完全应答者的中性粒细胞、白细胞和 NLR 平均数明显高于完全应答者。非完全应答患者的血红蛋白明显低于另一组应答者。接收者操作特征曲线分析显示，治疗前 Hb 和 NLR 的最佳临界值分别为 11 和 2.1。中性粒细胞与淋巴细胞比值临界点大于 2.1 与肿瘤体积较大、低 Hb、高血小板和高白细胞显著相关。结论：NLR 等血液学指标可以作为评估 LACC 患者化疗反应的一个简单而廉价的预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Predictive Value of Pre-treatment Hematological Parameters for Response to Definitive Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Study

Background: More than 90% of cervical cancers are related to chronic inflammation caused by HPV. Several studies have shown that laboratory hematological parameters can detect the severity of systemic inflammation. Objectives: Our current cohort study investigated the predictive role of pretreatment hematological parameters for response to definitive chemoradiotherapy in patients with locally advanced cervical cancer (LACC). Methods: Prospectively, patients with LACC who candidates for definitive chemoradiation at Shohadaye Haftom-e-Tir are and Firozgar Hospitals (Tehran, Iran) were included in our study between April 2021 and December 2022. Hematological parameters were obtained from the blood sample test and peripheral blood smear before treatment. All patients diagnosed in stage IB to IVA received a similar treatment protocol and follow-up. Patients were divided into complete clinical (CR) and non-complete clinical responses (Non-CR). Leukocyte, Lymphocyte, neutrophil, platelet, hemoglobin (Hb), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR), were documented and then compared between two groups of responders. We used receiver operating characteristic (ROC) analysis to investigate the predictive value of these hematological parameters. Results: Out of 34 patients who met the inclusion criteria, 25 (73/5%) patients were complete responders and 9 (26.5%) were non-complete responders. The average number of neutrophils, leukocytes, and NLR was significantly higher among Non-complete responders. Hemoglobin in patients with non-complete responses was significantly lower than that of the other group of responders. Receiver operating characteristic curve analysis showed that the optimized cut-off values for pretreatment Hb and NLR were 11 and 2.1, respectively. Neutrophil-to-lymphocyte ratio cut-off point > 2.1 is significantly associated with larger tumor size, low Hb, high platelet, and high leukocyte. Conclusions: hematological markers such as NLR can be a simple and inexpensive predictive factor to evaluate therapeutic response to chemoradiation in LACC patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Cancer Management ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.